NASDAQ · Biotechnology

Cocrystal Pharma, Inc. (COCP) Stock

$1.07 +0.00% NASDAQ: COCP Healthcare

Valuation

MetricValue
Price$1.07
Market Cap$14.75M
P/E Ratio-1.49
P/B Ratio15.12
P/S Ratio47.84
EPS (TTM)$0.00
52-Week High$2.03
52-Week Low$0.76
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-207.47%
ROA-213.77%
ROCE-497.29%
Gross Margin0.00%
Operating Margin0.00%
Net Margin-39.24%
Debt/Equity1.28
Current Ratio4.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-14.0M$-39.0M$-19.0M$-18.0M$-9.0M
Net Profit$-14.0M$-39.0M$-18.0M$-18.0M$-9.0M
EPS$-1.85$-4.77$0.00$-1.72$-0.78
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$79.0M$41.0M$31.0M$13.0M$10.0M
Total Liabilities$2.0M$1.0M$5.0M$4.0M$3.0M
Cash$59.0M$37.0M$26.0M$10.0M$7.0M
Borrowings$1.0M$0$2.0M$2.0M$2.0M

Latest News

Cocrystal Pharma Appoints James Sapirstein as Chief Executive Officer MT Newswires · Jun 3, 2026 Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer GlobeNewswire · Jun 3, 2026 COCP: Presentation Highlights CDI-988 Zacks Small Cap Research · Jun 1, 2026 Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza GlobeNewswire · May 26, 2026 Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results GlobeNewswire · May 15, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-13.0M$-21.0M$-15.0M$-16.0M$-8.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$26.0M$-22.0M$-11.0M$-16.0M$-3.0M
Free Cash Flow$-13.0M$-22.0M$-15.0M$-16.0M$-8.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.03
EV / EBITDA-1.58
FCF Yield-51.65%
Quick Ratio1.24
Interest Coverage0.00
Return 1Y-43.53%
Return 3Y-62.06%
Return 5Y-92.79%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BOLTBolt Biotherapeutics, Inc. $4.25 +16.44% -0.22 $8.17M 0.00%
BRTXBioRestorative Therapies, Inc. $1.91 +1.06% -0.10 $2.64M 0.00%
CINGCingulate Inc. $4.89 +0.20% -0.95 $65.86M 0.00%
DWTXDogwood Therapeutics, Inc. $1.43 +1.42% -0.18 $48.09M 0.00%
EVGNEvogene Ltd. $0.39 -2.13% -0.44 $3.36M 0.00%

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is led by CEO Sam Lee, employs 11 people, headquartered in US, publicly traded since 2012.

Cocrystal Pharma, Inc. (COCP) stock trades at $1.07 with a market capitalization of $14.75M. The stock is valued at a price-to-earnings (P/E) ratio of -1.49, price-to-book of 15.12, price-to-sales of 47.84. Over the past 52 weeks the stock has ranged between $0.76 and $2.03, and currently trades 47.3% below its 52-week high.

On profitability, Cocrystal Pharma, Inc. generates a return on equity (ROE) of -207.47%, return on capital employed of -497.29%, an operating margin of 0.00%, a net profit margin of -39.24%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.31 +0.33% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.67 +1.27%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides